Physicians views on EGFR wild-type/untested NSCLC treatment

20 June 2014

According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential factors in prescribing decisions for previously treated EGFR wild-type/untested non-small-cell lung cancer (NSCLC).

A news survey fro Decision Resources Group (DRG) also finds that improved median overall survival and increased progression-free survival are the greatest unmet needs in this indication. Surveyed oncologists express enthusiasm for PD-1 monoclonal antibody inhibitors and anticipate that Bristol-Myers Squibb (NYSE: BMY)/Ono Pharmaceutical's (TYO: 4528) nivolumab and Merck & Co's pembrolizumab will demonstrate efficacy advantages over currently available therapies. Interviewed thought leaders also expressed enthusiasm for AstraZeneca's (LSE: AZN) MEK inhibitor selumetinib in combination with docetaxel (generics) for the treatment of KRAS-mutant patients.

Other key findings from the DecisionBase report entitled include:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK